KMT2D

Across TCGA pan-cancer cohorts, KMT2D RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated KMT2D data layer compared with 13 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher KMT2D RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated KMT2D expression acts as an unfavorable survival marker, although some lineages such as SCLC and HNSC show a favorable association.

MESO, SCLC, and HNSC are the cancer types where KMT2D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	All	0.287	0.437	.005	56	view →
SCLC	OS	Median	All	0.473	0.212	.002	53	view →
HNSC	DFS	Tertile	All	0.379	0.281	.004	45	view →
KIRC	DFS	Quartile	All	0.831	0.522	.002	34	view →
LGG	OS	Median	All	0.747	0.923	<.001	23	view →
LUSC	DFS	Tertile	III,IV	0.417	0.951	.007	23	view →
LIHC	DFS	Tertile	All	0.477	0.608	.009	13	view →
THYM	DFS	Tertile	II,III,IV	1.000	0.525	.009	12	view →
ACC	DFS	Quartile	All	0.431	0.870	<.001	10	view →
THCA	OS	Tertile	II,III,IV	0.742	0.896	.017	10	view →
CESC	DFS	Quartile	III,IV	0.383	0.866	.033	8	view →
GBM	DFS	Quartile	All	0.425	0.201	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

KMT2D–MESO (DFS)

Open the MESO breakdown →